Physical Activity Intervention for Gestational Diabetes

Gestational Diabetes Clinical Trial

— GDM  

Official title:

Physical Activity Intervention for Gestational Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03664089
• Other study ID #: 18-00178
• Status: Completed
• Phase: N/A
• Start date: September 10, 2018
• Est. completion date: July 1, 2022

Study information

• Verified date: July 2022
• Source: Nationwide Children's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Gestational diabetes mellitus (GDM) portends an immediate, increased risk for Type 2 diabetes mellitus (T2DM). The increased risk associated with having GDM is compounded by excess weight retention. Therefore, the weeks and months immediately after a GDM-complicated pregnancy present an optimal window to initiate lifestyle changes to prevent or delay T2DM. The long-term goal is to prevent T2DM among women with GDM. This study's objective is to evaluate the efficacy of a novel, yet simple, activity-boosting intervention on weight loss among women with GDM.

Description:

Gestational diabetes mellitus (GDM) portends an immediate, increased risk for Type 2 diabetes mellitus (T2DM). The increased risk associated with having GDM is compounded by excess weight retention, a common issue after any pregnancy. Considering excess weight is the best predictor of developing T2DM, the weeks and months immediately after a GDM-complicated pregnancy present an optimal window to initiate lifestyle changes to prevent or delay T2DM. The long-term goal is to prevent T2DM among women with GDM. This study's objective is to evaluate the efficacy of a novel, yet simple, activity-boosting intervention on weight loss among women with GDM in a parallel two-arm randomized controlled trial (n=80 women/arm, N=160). The intervention uses ankle weights (2.5 pounds [1.1 kg]) worn on each ankle during routine daily activities (e.g., cleaning, cooking, child care) to increase energy expenditure. The central hypothesis, based on existing literature and preliminary data, is that postpartum women with GDM will adopt an intervention that requires minimal additional time outside of their daily activities. We anticipate that this will result in additional weight loss that is clinically significant when compared with controls who only receive standard information on recommended physical activity. The rationale for the proposed research is that once an intervention that both improves T2DM factors and is easily adopted by women with GDM is known, early intervention specific to this restricted timeframe can be implemented.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: July 1, 2022
• Est. primary completion date: February 22, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18+ years
• Diagnosed with GDM in current pregnancy
• English language ability adequate for participation
• Plan to remain in the area for study duration
• Ability to provide informed consent

Exclusion Criteria:

• Prior Type 1 or Type 2 diabetes
• Pregnant with multiples (e.g., twin, triplets, etc.)
• Premature infant [<35 completed weeks gestation (assessed after delivery, before randomization)]
• Heart disease, serious illness, or conditions that may impede or prohibit participation in either study arm
• Pre-pregnancy BMI <18.5 (underweight)
• Live outside 35 mile radius of Ohio State University
• Woman is an appointed surrogate
• Infant will be adopted after delivery

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes, Gestational
• Gestational Diabetes

Intervention

Behavioral:
• Ankle weights (2.5 pounds [1.1 kg]/ankle)
Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
• Control
Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.

Locations

Country	Name	City	State
United States	Nationwide Children's Hospital	Columbus	Ohio

Sponsors (4)

Lead Sponsor	Collaborator
Sarah Keim	American Diabetes Association, Ohio Department of Health, Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight loss	Postpartum weight loss will be defined as weight change from initial weigh-in at NCH Visit 1 to final weigh-in at NCH Visit 2. Weight will be measured in person using the Tanita.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary	Body Fat %	Percent body fat will be defined as the change in initial measurement at NCH Visit 1 to final measurement at NCH Visit 2. Percent body fat will be measured in person using the Tanita.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary	BMI	BMI will be defined as the change from initial measurement at NCH Visit 1 to final measurement at NCH Visit 2. BMI will be measured using the Tanita for weight and obstetric medical record for height.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary	Waist-hip Ratio	Waist circumference (cm) will be assessed at the middle point between the ribs and the iliac crest, with the participant standing. Hip circumference (cm) will be measured at the widest circumference of the buttocks. Change in circumference will be defined as the change from initial measurement at NCH Visit 1 to final measurement at NCH Visit 2. Waist-hip ratio will be measured in person using metric cloth tape.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary	Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Oral Glucose Tolerance Test (OGTT)	Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. A fasting 2-hour, 75g OGTT will be conducted during both NCH visits. Glucose tolerance will be measured in mg/dL.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary	Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: HOMA	Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Insulin sensitivity (ß-cell function) will be measured using the Matsuda index and HOMA-IR. Matsuda index score and HOMA-IR will be determined based on insulin values (µU/mL) and glucose values (mg/dL) obtained from the OGTT.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary	Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Hemoglobin A1c (HbA1c)	Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. HbA1c will be analyzed as a percentage.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary	Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Leptin	Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Fasting serum leptin will be measured in ng/mL.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary	Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: High sensitivity c-reactive protein (hs-CRP)	Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. hsCRP will be measured in mg/L.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary	Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Adiponectin	Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Adiponectin will be measured in µg/mL.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)
Secondary	Glycemia and Associated Biomarkers of Insulin Resistance and Metabolic Health: Lipid Panel	Blood will be collected during both visits at NCH and sent to the NCH lab for analysis. Lipids will be analyzed including total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides. Lipids will be measured in mg/dL.	NCH Visit 1 (25-35 days postpartum) to NCH Visit 2 (220-240 days postpartum)